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Teresa Coelhof, Theodore Kyriakidesg, from the European Network for
TTR-FAP (ATTReuNET)Purpose of review
These recommendations highlight recent experience in genetic counselling for the severe autosomal-
dominant, late-onset transthyretin familial amyloid polyneuropathy (TTR-FAP) disease, and present a
structured approach towards identification and monitoring of asymptomatic carriers of the mutated gene.
Recent findings
The effectiveness of current treatment options is still limited in patients with TTR-FAP beyond stage I.
Diagnosis in the early stages of TTR-FAP is essential to prevent or delay the progression of disease. Existing
legal and cultural issues differ among countries within Europe. Experts of the European Network for TTR-
FAP (ATTReuNET) concluded that genetic counselling for diagnosed individuals and at-risk family members
is mostly beneficial and should be carried out with care by trained professionals. Systematic and regular
monitoring of an asymptomatic carrier is necessary to detect early signs of TTR-FAP and maximize the
effectiveness of treatment. This includes five areas of assessment: history/clinical examination, sensorimotor
function, autonomic dysfunction, cardiac function, and renal function. At least two related symptoms and
positive biopsy findings are required to confirm diagnosis of TTR-FAP.
Summary
Early detection of TTR-FAP is essential to improve the prognosis of TTR-FAP. ATTReuNET recommends
genetic counselling and routine monitoring for asymptomatic carriers of TTR-FAP.
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Familial amyloid polyneuropathy (FAP) is a rare,
life-threatening, autosomal-dominant, systemic dis-
ease caused by the extracellular deposition of insolu-
ble amyloid fibrils formed by mutated transthyretin
(TTR) [1]. Todate,more than100missensemutations
in the TTR gene have been described worldwide;
however, not all are amyloidogenic [2,3,4
&
]. Most
of these TTR variants are found in single individuals
or within a few families, whereas a few are prevalent




according to updated Human Genome Variation
Society nomenclature) [6] was the first to be iden-
tified and is by far the most common [7].
Transthyretin FAP (TTR-FAP) has an estimated
prevalence of one in 100000 in the USA [8] and
Europe [9]. It is considered an endemic disease inht © 2016 Wolters Kluwer Health, Inc. All rights reserved.
rs Kluwer Health, Inc. All rights reserved. www.co-neurology.com
KEY POINTS
 As treatment for TTR-FAP is most effective in early
stages of the disease, early diagnosis and treatment
are key for better prognosis.
 Genetic counselling by a multidisciplinary team is
recommended for presymptomatic genetic testing for
TTR-FAP as well as subsequent regular follow-up of
identified carriers.
 Regular monitoring of an asymptomatic TTR-FAP carrier
should focus on five areas of assessment for early signs
and symptoms: history/clinical examination,
sensorimotor function, autonomic dysfunction, cardiac
evaluation, and renal function.
Consensus for transthyretin amyloid neuropathyspecific areas of Europe (northern Portugal, Sweden,
Cyprus, and Majorca) and in Japan [1,5
&
,10].
TTR-FAP presents in many different forms and
with considerable variation in signs and symptoms
among individuals and across geographic locations
[5
&
]. Symptoms are mainly neuropathic, includ-
ing a heterogeneous presentation of peripheral
(sensory and motor) and autonomic neuropathy.
In addition, gastrointestinal impairment, cardio-
myopathy, nephropathy, or ocular deposition can
be associated with neurological disease [5
&
].
Diagnosis in the early stages of TTR-FAP is essen-
tial to allow for timely treatment to prevent or delay
disease progression. Early recognition remains a
challenge, with delayed diagnosis still occurring,
often because of misdiagnosis [11–16]. Time to
diagnosis can be as long as 4 years, especially among
thosewithout a family history of FAP, because of low
penetrance of the gene or the rare occurrence of
de novo mutations [11–13,16,17
&&
].
An additional challenge arising once the disease
is recognized in a single family member relates to
proper genetic counselling and the offer of presymp-
tomatic testing (PST) for the TTR gene to at-risk
relatives, followed by effective management of
asymptomatic individuals carrying the TTR gene
variant [18
&&
]. However, guidelines for early
monitoring and diagnosis of asymptomatic carriers
of mutated TTR-FAP remain lacking.
In November 2012 and March 2014, two round-
table European Expert Meetings titled ‘Optimising
the Management of TTR-FAP in Europe’ were
attended by 15 TTR-FAP experts to share expertise
and achieve a consensus on the diagnosis and
clinical management of TTR-FAP. These experts
are members of an emerging group that is provi-
sionally called the European Network for TTR-FAP
(ATTReuNET), covering 10 European countries and
nine national reference centres. Copyright © 2016 Wolters Kluwer 
S28 www.co-neurology.comThe questionnaire used in preparation for the
meetings (Table S1, http://links.lww.com/CONR/
A38) and a summary of the expert participants
of ATTReuNET (Table S2, http://links.lww.com/
CONR/A38) are provided in the supplementary
appendix. In this article, we address the medical,
psychological, ethical, and legal aspects of PST
among individuals at risk for TTR-FAP, and provide
recommendations for following up asymptomatic
carriers of TTR-FAP until their first symptoms mani-
fest and they become diagnosed patients. Specific
questions related to these issues were addressed by
the ATTReuNET group after analysing available
published data. Recommendations were developed
based on this analysis and face-to-face expert
discussions.Presymptomatic testing for transthyretin
familial amyloid polyneuropathy
TTR-FAP is an adult-onset disease, and carriers of the
amyloidogenic variant often do not present symp-
toms until late adulthood [5
&
]. PST for TTR in at-risk
people is now widely available, either at referral
centres or at local genetic laboratories [16].
Although accessibility to PST has increased world-
wide in the past decade, specific guidelines on the
requirements for such testing in TTR-FAP do not
exist. As the positive predictive value of PST may
vary depending on different populations and
mutations, this should also be considered when
assessing the risk of developing TTR-FAP for each
patient. For example, the prevalence of the Val30-
Met TTR mutation in the endemic areas of Sweden
is close to 2% [19]; however, the penetrance of the
trait varies and is generally low [20], which dimin-
ishes the predictive value of PST. In consideration of
these aspects and the fact that prophylactic
measures are not available for TTR-FAP, the ATTReu-
NET group discussions focused on whether, how,
and when PST should be offered, as well as how to
manage the counselling process.
Offer of presymptomatic testing in
transthyretin familial amyloid
polyneuropathy
It is generally accepted that the greatest medical
benefit from PST can be achieved for diseases for
which treatment and/or prophylactic measures are
available [21
&
]. In TTR-FAP, the continuous change
in therapeutic options observed in the past 5 years,
including medical treatment with tafamidis in the
early stage of the disease [22], evidence of possible
long-term benefit of liver transplantation in selected
cases [23], and novel drugs under clinical develop-
ment [24], has contributed to changes in theHealth, Inc. All rights reserved.
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Presymptomatic testing of TTR-FAP Obici et al.perception of PST for this disease among physicians
and families [25]. PST may allow for close and tail-
ored clinical monitoring until very early signs of the
disease arise, prompting treatment initiation, and
can help with decisions about personal and family
planning, including prenatal and preimplantation
diagnosis (PND and PID, respectively) [26
&
,27].
However, considering the potentially over-
whelming impact on personal and family life from
a positive test result, a request of PST for TTR-FAP
shouldalwaysoriginate fromthepersonaffected, and
communication strategies should be put in place by
health professionals to ensure that PST is their
autonomous choice [21
&
]. Limited data collected to
date on the psychological impact of PST indicate that
it is of potential value in TTR-FAP [25,28
&&
,29]. How-
ever, the psychological distress to the patient – in
terms of both anxiety and depression, irrespective of
a positive or negative result – warrants follow-up and
possible long-term psychological support [25]. Inter-
estingly, women aremore likely to exhibit long-term
anxietyandemotionalproblemsevenafteranegative
result, termed ‘survivor guilt’ [29].
Timing of presymptomatic testing
Apart from well-acknowledged general recommen-
dations to avoid PST in minors [30], no guidance is
available concerning the best time to offer PST in
adults. Considerations about specific genotype–
phenotype relationships, age at disease onset, and
severity in affected relatives should be taken into
account when offering PST [28
&&
]. In particular, the
possibility of genetic anticipation, which is the
earlier age of onset in subsequent generations of
index cases, should be taken into consideration in
endemic regions, with higher likelihood of anti-
cipation and earlier age of onset in male offspring
inheriting the disease from the mother [31,32,33
&
].
Early and late-onset disease variants can coexist in
the same family, and an understanding of anticip-
ation should be considered when counselling off-
spring and following up mutation carriers [33
&
].
Paneque, et al. [28
&&
] showed that prolonged aware-
ness of TTR-FAP in the family and longer personal
experience of the disease might contribute to a
better adaptation to the knowledge of personal
genetic status, as well as reducing the psychological
burden of the results. On the contrary, individuals
who become aware of the disease in their family
only recently before deciding to undergo PST have
more difficulties coping with the results [28
&&
].
Genetic counselling for presymptomatic
testing
Genetic counselling in the context of PST for
late-onset diseases presents a series of ethical, Copyright © 2016 Wolters Kluwe
1350-7540 Copyright  2016 Wolters Kluwer Health, Inc. All rights resepsychological, and practical questions. This includes
the advantages and disadvantages of knowing a diag-
nosiswell in advanceof theappearanceof symptoms,
the difficulty of living with the results, and the
potential impact of this information on reproduc-





,34]. In common with other late-onset
neurodegenerative diseases and familial cancer syn-
dromes, genetic counselling is of utmost importance
when offering PST for a disabling disease like TTR-
FAP.Althoughno specific protocols havebeen imple-
mented for TTR-FAP, guidelines applicable to several
different adult-onset monogenic conditions have




are mainly intended to share the principles and
objectives of PST, limiting specific indications (i.e.
the number and timing of sessions) to enable prac-
titioners to individualize the protocol according to
their judgement and expertise. However, the quality
and the content of the information provided in the
counselling process, the setting in which communi-
cation takes place, the skills of health professionals
involved in the service and their capacity to support
the psychological impact of the results should be
taken into consideration when providing PST [21
&
].
Several studies have evaluated how counselling
can be optimized to provide the best outcome,
including consideration of the number of counsel-
ling sessions, time spent, consultation environment,
multidisciplinary approach, topics for pretest discus-





studyof individuals at risk for TTR-FAP indicated that
positive perception of PST by consultants also relates
to the adjustment of the counselling protocol on a
‘case-by-case’ basis, reflecting counsellor flexibility,
experience, self-confidence, and training in estab-
lishing empathic relationships [18
&&
].
Prenatal and preimplantation diagnosis
Overall, there is limited experience with PND and
PID in TTR-FAP in Europe, and most has been gath-
ered in Portugal and, recently, France. For example,
in Portugal, both PND and PID are currently avail-
able, with a strong recommendation from the
National Council for Medically Assisted Procreation
(Conselho Nacional de Procriac¸a˜o Medicamente
Assistida) for existing patients to undertake PID
[37,38]. A survey conducted among FAP carriers
between 18 and 55 years found that the choice for
controlled reproduction is related to their knowl-
edge about the disease and current socioeconomic
position, emphasizing the need to educate families
about TTR-FAP [27]. Differences in legal and cultural
issues on preimplantation and/or termination of
pregnancy between countries within Europe remainr Health, Inc. All rights reserved.
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Table 1. ATTReuNET-recommended approach to genetic counselling of asymptomatic carriers
Genetic counselling should only be employed for those aged 18 years
PST should be at the request of the patient
There should be a multidisciplinary approach to genetic counselling, and it should be clear how each team member should be involved
Timing of genetic counselling should be determined according to whether the region is characterized by early or late-onset, sporadic, or
endemic cases
PST requests outside of genetic counselling should not be permitted, unless allowed according to national guidelines and regulations
There should be ongoing communication after PST, and the information provided should be updated and current
ATTReuNET, European Network for TTR-FAP; PST, presymptomatic testing.
Consensus for transthyretin amyloid neuropathydiverse [39]; therefore, providing general recom-
mendations for this setting is a challenge.Expert recommendations for genetic
counselling and presymptomatic testing
Based on available literature and the long-term
experience gathered at the European centres
represented by the expert group, ATTReuNET agreed
that PST may be carried out safely in TTR-FAP. This
recommendation is based on the emerging benefits
of detecting asymptomatic carriers, given the grow-
ing availability of medical treatment for this disease
and the need to avoid misdiagnosis. However, PST
testing should always remain a personal choice, and
long-term medical monitoring can be offered as an
alternative to those individuals who decide not to
undertake PST. The approach and methodology
shown in Table 1 and Figure 1, respectively, are
recommended for genetic counselling for PST in
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FIGURE 1. ATTReuNET-recommended methodology in genetic
TTR-FAP; PST, presymptomatic testing; TTR-FAP, transthyretin famil
local regulations.
S30 www.co-neurology.comBecause of different rules and regulations among
European countries [35,39], no specific recommen-
dation can be provided to healthcare professionals
about who should be involved in genetic counsel-
ling for TTR-FAP. Genetic counsellors, physicians
with expertise in TTR-FAP, and psychologists/psy-
chiatrists should work together as a team whenever
possible to provide amultidisciplinary environment
that facilitates a sustainable, long-term relationship
with patients and at-risk family members (Table 2).
A team approach that includes a clinical expert in
TTR-FAP will likely improve the amount and quality
of the information provided, whereas fostering,
from the very beginning, an empathetic relation-
ship with a key person who will be responsible for
the index case, should the test result be positive [34].
Genetic counsellors and psychologists can improve
the communication process within the team,
increase staff skills and experience, and help clini-
cians to deal with any ambivalent feelings and
personal fears [34].Health, Inc. All rights reserved.
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Table 2. ATTReuNET-recommended minimal monitoring of asymptomatic carriers
Follow-up Confirmation
Baseline 12 monthsa of diagnosis Specialist involvement




















Temperature pain sensitivity in the feet and legs H H Confirmatory
NIS H H Biopsy evidence of
amyloid
Electromyography, NCS H H
Sympathetic skin response H









Heart rate response/variabilityd H H
Gastrointestinal H H
Sweat teste,f,h H H
Erectile dysfunction H H
ATTReuNET, European Network for TTR-FAP; ECG, electrocardiography; NCS, nerve conduction study; NIS, Neurological Impairment Scale; NT-proBNP, N-
terminal pro–B-type natriuretic peptide; TTR, transthyretin.
aDepending on age of patients (higher frequency for younger patients), patient’s preference, and clinical or family history.
bMinimum requirement for specialist involvement.
cNot routinely performed; usually only seen in clinical research protocols or in endemic areas (e.g. Porto).
dPatients with late-onset disease or non-Val30Met TTR variant.
eMeta-iodobenzylguanidine scintigraphy not mandatory.
fNot routine in Sweden among asymptomatic patients.
gIn Sweden, tests for proteinuria carried out instead.
hSUDOSCAN 3-min test.
Presymptomatic testing of TTR-FAP Obici et al.Although two pretest sessions are generally
recommended in published protocols, the number
and timing of sessions can vary according to coun-
sellor/team judgement [21
&
,35]. Overall, PST in at-
risk relatives may be postponed from the time of
diagnosis of the index case, particularly if the disease
is an unexpected finding because of a lack of family
history. During this period, the priority usually
remains with the index case, with the goal being
to limit the psychological impact of the new diag-
nosis on the whole family and allow time to estab-
lish a long-term relationship between patient,
family, and clinician before wider counselling
is implemented. Copyright © 2016 Wolters Kluwe
1350-7540 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseHowever, siblings of diagnosed patients/index
cases may have a higher priority for genetic coun-
selling, especially for those close to the age of poten-
tial disease onset, because they are at the greatest
risk for developing symptomatic disease in the short
term and could even present with mild signs of
disease at first evaluation after a positive test [40].
In contrast, offspring of diagnosed patients/index
casesmust be approachedwith sensitivity because of
the high likelihood of emotional reactions (e.g.
blame, anger, fear) based on knowledge of inherit-
ing a serious disease that cannot be prevented and
has limited treatment options available [28
&&
]. Time
is essential for the family to adjust to diagnosis andr Health, Inc. All rights reserved.
rved. www.co-neurology.com S31
Consensus for transthyretin amyloid neuropathymake subsequent decisions (e.g. impact on repro-
duction, financial matters, career planning) [21
&
].
Management of asymptomatic carriers
Baseline assessment and subsequent regular
monitoring of an asymptomatic carrier may be
effective in detecting changes in the very initial
stages of the disease, given that early diagnosis
and prompt treatment currently provide the best
chance of minimizing further nerve degeneration
[41]. In fact, available treatments appear to be most
effective in patients with stage I TTR-FAP [1,5
&
,42],
whereas data supporting efficacy in more advanced
stages are limited [43,44]. An effective treatment
could delay disease progression, but recovery from
established neurological deficits would not be
expected. Several studies have been performed to
identify neurophysiological markers of early small
fibre damage and signs of very initial nerve injury
[45,46,47
&&
]. Laser-evoked potentials, sympathetic
skin responses, cold and warm detection thresholds
and heart rate variablity, as indicators of small fibre
functioning, have all proven greater sensitivity at
detecting early signs of TTR-FAP than conventional
neurophysiological large fibre tests [45,46]. In
addition, assessment of sudomotor function by
means of Quantitative Sudomotor Axon Reflex Test
or SUDOSCAN (Impeto Medical, San Diego, CA)
may help to disclose early abnormalities of distal
small nerve fibre function. There is also evidence to
suggest that high-resolution magnetic resonance
neurography may detect and quantify peripheral
nerve injury in the lower limbs even before TTR-
FAP becomes symptomatic in carriers [47
&&
].
It is anticipated that additional understanding
of the TTR-FAP disease wlll be provided by the
international collaborative prospective THAOS
(TTR Amyloidosis Outcomes Survey) registry
[48,49
&
]. However, to date, no consensus guidelines
are available for monitoring asymptomatic TTR
carriers, and different protocols have been locally
implemented according to everyday practice. These
protocols reflect centre-based experiences that are
closely related to the spectrum of mutations and
phenotypic characteristics of the disease in each
region. For example, in populations in which a
mixed neurological-cardiac phenotype is mostly
observed because of a wide spectrum of TTR variants
(e.g. France, Italy), cardiac evaluations may be
included very early in carriers at follow-up [26
&
].
In the Portuguese population, TTR-FAP frequently
causes early conduction abnormalities in the
absence of echocardiographic signs of cardiomyop-
athy at onset and may also damage the kidneys in
the initial disease stages. Therefore, assessment of
cardiac parameters, particularly ECG and 24-hour Copyright © 2016 Wolters Kluwer 
S32 www.co-neurology.comHolter monitoring, and urine examination are rou-
tinely recommended [50,51]. Individuals belonging
to families with early-onset TTR-FAP consistently
undergo more frequent neurological investigations.
Finally, the age at first evaluation relative to the
expected age of onset according to genotype may




Expert recommendations for management of
asymptomatic carriers
Methodologically, ATTReuNET identified five areas
of assessment – namely, history/clinical examin-
ation, sensorimotor function, autonomic dysfunc-
tion, cardiac evaluation, and renal function – and
agreed on the minimum set of evaluations that
should be performed at the time of the first visit
after a positive PST (Table 2). To avoid emotional
distress, it is recommended that invasive tests are
avoided and that the number of evaluations per-
formed each year is limited. The purpose of the
follow-up is to provide the earliest identification
of disease onset to allow prompt initiation of treat-
ment. Educating presymptomatic carriers to recog-
nize the early disease-related symptoms is of
paramount importance. Assessments that have lim-
ited sensitivity and specificity and are not yet able to
guide treatment decision-making should be avoided
or performed only in the context of a clinical obser-
vational research study.
It is recommended that the frequency of follow-
up should vary according to the patient’s age, age of
onset in the family, and sex of the parent who carries




] (Table 2), with the
anticipation effect through maternal transmission
also taken into consideration [53].Monitoring could
becomemore frequent when the typical age of onset
for that particular mutation/family history is
reached. Abnormal findings can prompt a shorter
follow-up to clarify their clinical significance. Over-
all, routine follow-up is recommended yearly in
countries with early-onset Val30Met TTR-FAP, such
as Portugal, as well as for individuals with late-onset
disease. The recommended age to start these evalu-
ationswill probably be themajor difference between
the two types of population.
Biopsies are not routinely recommended for
long-term monitoring of asymptomatic carriers
because of their invasiveness. In addition, a positive
biopsy in the absence of any functional abnormality
has no predictive value on the onset of the disease
[5
&
]. The presence of TTR-FAP symptoms is required
to initiate treatment even in early-onset Met30
Portuguese carriers with evidence of amyloid depos-
its from a biopsy [41]. However, biopsy can become
helpful to clarify unexpected abnormal findings. OnHealth, Inc. All rights reserved.
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Presymptomatic testing of TTR-FAP Obici et al.the other hand, the low sensitivity of biopsies in
early stages and/or false-negative results should
always be considered before dismissing a clinical
suspicion of symptomatic disease [1,5
&
,42,54].
There are insufficient data available to allow for
an absolute definition of what represents the min-
imal evidence of neurological involvement to
prompt treatment. Despite the lack of guidance, it
is important to be cautious when classifying a carrier
as affected, because a diagnosis will determine
initiation of treatment. Therefore, more than one
abnormal finding should be obtained before a diag-
nosis can be established. The ATTReuNET members
recommended that the key diagnostic indicators for
TTR-FAP be at least two of the following TTR-FAP-
related symptoms, followed by a biopsy: patient-
perceived symptoms or changes, changes from base-
line measurements, or cardiac indicator (cardiac
microvoltage, pseudomyocardial infarction, or
heart blocks).CONCLUSION
TTR-FAP is a rare but ubiquitous and life-threatening
genetic disease. Early diagnosis and intervention is
critical, given the still-limited time window for
effectiveness of treatment, including liver trans-
plant and pharmacotherapy. PST is an important
tool for early patient diagnosis, particularly within
those areas in which TTR-FAP is endemic, and will
feature strongly in diagnostic protocols of the
future. Genetic counselling and PST should be
approached with care and carried out by a multi-
disciplinary team. Overall, there is agreement across
Europe that proper genetic counselling in TTR-FAP
has beneficial effects, with no significant disadvan-
tages. Raising awareness, establishing TTR-FAP
expert networks, and having referral channels to
the TTR-FAP NRCs will help to ensure timely detec-
tion of the disease and effective delivery of optimal
care to patients.
From an ethical perspective, the provision of
genetic counselling to individuals with a diagnosis
of TTR-FAP is mandatory to provide knowledge of
the disease; however, PST should be performed only
upon informed patient request. A good long-term
relationship between physician, patient, and family
may improve adherence to follow-up requirements
in asymptomatic individuals after a positive
presymptomatic test.
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